QuantiScientifics

QuantiScientifics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

QuantiScientifics is a privately-held, US-based biotech firm founded in 2015 that operates at the intersection of diagnostics and AI/machine learning. The company has developed a proprietary multiplex assay platform (A2 technology) that simplifies and accelerates the creation of custom immunoassays for research and diagnostic use. It generates revenue through the sale of assay plates, kits, and contract research/consulting services, primarily targeting the food allergy and sensitivity testing markets. Leadership is anchored by its founder, an experienced inventor in microarray technology, indicating a deep technical foundation.

AllergyFood IntoleranceInflammatory Diseases

Technology Platform

A-squared (A2) oligo-link technology for creating multiplex antibody microarrays in standard well plates via oligonucleotide hybridization, without printing.

Opportunities

The growing global demand for comprehensive, multiplex food allergy and sensitivity testing presents a direct market.
The flexible A2 platform also creates opportunities in custom assay development as a service for pharma and biotech companies in biomarker research and companion diagnostic development.

Risk Factors

Primary risks include competition from large, entrenched diagnostic companies, the cost and complexity of obtaining regulatory clearance for clinical diagnostics, and the company's limited scale and resources to commercialize broadly and support a large customer base.

Competitive Landscape

QuantiScientifics competes in the multiplex immunoassay space against large diversified players like Luminex (xMAP), Meso Scale Discovery (MSD), and Thermo Fisher, as well as other niche assay developers. Its differentiation lies in the simplicity and customizability of its plate-based, printing-free A2 platform for research and specialty diagnostic applications.